Toronto-based startup ACTO, which offers training, analytics, and data tracking for life sciences salespeople, has acquired Scrimmage, a Minneapolis-based mobile learning company. The purchase price of the deal was not disclosed.
“Through this partnership, we’ll catalyze change and unlock value across the life sciences.”
– Parth Khanna, CEO of ACTO
ACTO has acquired Scrimmage’s product, in addition to all of Scrimmage’s 50 clients, team members, and existing partnerships. Scrimmage CEO Derek Lundsten is set to join ACTO as a senior strategic advisor.
Scrimmage will continue to serve its existing clients, which operate across a variety of verticals, including both life sciences and non-life-sciences. The addition of Scrimmage’s customers brings ACTO’s overall customer base to more than 100.
Founded in 2014, ACTO offers analytics, training, and data tracking for life sciences salespeople. The startup has developed an artificial intelligence-powered platform, which provides mobile experiences intended to educate, engage, and assist life sciences sales professionals.
Some of ACTO’s app features include “mobile microlearning,” a digital briefcase, remote coaching, virtual training, and live events that give global pharmaceutical and medical device companies access to real-time insights. The company states the tools are aimed to help clients promote clinical value, increase sales, drive brand impact, and reduce compliance risk.
RELATED: Yourgene to acquire BC BioTech Coastal Genomics for up to $17.9 million CAD
Using gamification, social features, and mobile learning strategies, Scrimmage aims to help life sciences companies engage learners and drive field performance with accessible, engaging, and integrated people-first tools. Scrimmage launched its flagship app in 2010 and currently serves over 100,000 active global users and more than 50 enterprise clients across a broad spectrum of industries.
“The Scrimmage team shares our passion for using innovation and advanced technologies to move healthcare forward,” said ACTO CEO Parth Khanna. “Through this partnership, we’ll catalyze change and unlock value across the life sciences for field sales personnel, healthcare providers, patients, and everyone in between.”
News of the acquisition follows ACTO’s announcement of its $11.5 million USD Series A round of financing, which closed in April. Some of ACTO’s investors include MaRS IAF, Panache Ventures, Salesforce Ventures, and Resolve Growth Partners.
“By joining forces with ACTO, we’ll be opening the next chapter in our combined growth, and bringing our transformative solutions to an even wider audience, as we expand the ACTO family,” said Lundsten.
Image source ACTO.